We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Rac-enhanced CAR immunotherapy: RaceCAR
- Prof. Denise Montell
-
34. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1
- Prof. Kevin Harrington
-
35. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2
- Prof. Kevin Harrington
-
36. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
37. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
38. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
39. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
40. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
41. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
42. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
43. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
45. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
46. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
47. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
48. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
49. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
50. Cow’s milk allergy: the future
- Dr. Carina Venter
-
51. Cow's milk allergy: management
- Dr. Carina Venter
-
52. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
53. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
54. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
55. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
56. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
57. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
58. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
59. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
60. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
61. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
63. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
64. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
65. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
66. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
67. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
68. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
69. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
70. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
71. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
72. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
73. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
74. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
75. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
76. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
77. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
78. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
79. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
80. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
81. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
82. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
83. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
84. AI and big data in drug discovery
- Mr. Ed Addison
-
85. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
86. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
87. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
88. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
89. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
90. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
91. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
92. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
93. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
94. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
95. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
96. New drugs for asthma
- Prof. Peter Barnes
-
97. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
98. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- Programmable DNA targeting modules
- Effector domains: transcription modulators
- Fusions with effector domains
- Human disease and transcriptional dosage
- Haploinsufficiency
- Zygosity of pathogenic genes
- Around 15% of our genes could be haploinsufficient
- Treatments for haploinsufficient disease
- AAV vectors have a 4.7Kb limit on cargo
- Transcriptional modulation-dCas9-fusions
- Can CRISPRa correct haplinsufficiency?
- Haploinsufficiency of SIM1 leads to obesity
- SIM1 is downstream of the Leptin-Mc4r pathway
- CRISPRa targeting to rescue Sim1 obesity
- CRISPRa upregulates Sim1 in vitro
- Sim1 CRISPRa upregulation strategy: in vivo
- Sim1 promoter CRISPRa rescues obesity
- Sim1 enhancer CRISPRa rescues obesity
- Sim1 CRISPRa targeting can define tissue specificity
- CRISPRa-AAV upregulates Sim1 in the hypothalamus
- Postnatal rescue of neuroendocrine obesity
- Sim1-CRISPRa-AAVs have long lasting effect
- Can CRISPRa strategy work for other HI genes?
- Leptin-Mc4r pathway
- CRISPRa-AAV rescues Mc4r haploinsufficiency
- Overcoming size limitation of AAV gene therapy
- Summary
- Loss of function of Lama2-MDC1A
- CRISPRa targeting alternative/redundant gene
- FABP4 expression is linked to many diseases
- CRISPRi to downregulate the biomarker genes
- Autosomal dominant: Huntington's Disease
- ZF-KRAB to downregulate the pathogenic gene
- DNA methylation modulation
- DNA looping modulation
- Advantages and disadvantages
- Acknowledgements
Topics Covered
- Programmable DNA targeting modules
- Effector domain functions and possibilities
- Haploinsufficiency and its role in disease
- CRISPRa targeting strategy to rescue Sim1 obesity
- CRISPRa targeting strategy to treat Mc4r haploinsufficiency
Links
Series:
Categories:
Talk Citation
Matharu, N. (2021, December 13). Modulating gene expression to treat diseases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 5, 2025, from https://doi.org/10.69645/BOTL2560.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Navneet Matharu has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Cell Biology
Transcript
Please wait while the transcript is being prepared...
0:00
Hi, everybody. This is Navneet Matharu; I'm an Assistant Professor
in the Department of Bioengineering and Therapeutic Sciences at UCSF.
The topic of my talk today is
future gene therapy strategies for modulating gene expression.
It's my pleasure to discuss with you today some of the recent advances in research that
highlight the use of non-editing versions of gene editors to treat genetic disorders.
0:28
Broadly, there are three versions of gene editors that are
explored in the last couple of decades first-generation:
zinc-finger nucleases, second-generation: TALENs,
and third-generation: the CRISPR system.
All of these have programmable DNA recognition or targeting modules.
Zinc finger nucleases have C2H2 zinc-finger domains for DNA recognition.
TALENs have TAL effector DNA recognition and binding domains and CRISPR is
a ribonuclease complex where DNA target recognition is guided by the guide, RNA.
Zinc fingers or TALs can be made into nucleases by fusing
the FOK1 restriction enzyme that creates a single-strand DNA break.
It takes two zinc-finger FOK when fusion molecules to make a double-strand DNA break.
CRISPR-Cas9 mind hazard to new peers domains that can make double-stranded DNA break.
These editors can be programmed into nuclease deficient versions, for example,
if you don't fuse a FOK1 to zinc-finger or TAL
these molecules are nucleus deficient on their own.
To make nuclease deficient CRISPR Cas9 we can mutate
these two catalytically active nucleus domains such that it loses
its DNA editing ability and we can make a dead Cas9 version out of it.
Now, these DNA targeting modules can be fused to any effective domains that
can perform a variety of biochemical functions at the target locus.
These effector domains that can modulate
the target gene expression are mostly transcription activators or repressors.